Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AKBA – Akebia Therapeutics Inc.

Akebia Therapeutics, Inc.
AKBA
$3.97
Name : Akebia Therapeutics, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,042,664,896.00
EPSttm : -0.21
finviz dynamic chart for AKBA
Akebia Therapeutics, Inc.
$3.97
7.59%
$0.28

Float Short %

7.83

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.06

EPS Last/This Y

0.28

EPS This/Next Y

0.32

Price

3.96

Target Price

7.4

Analyst Recom

1

Performance Q

108.95

Relative Volume

1.56

Beta

0.83

Ticker: AKBA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08AKBA2.620.331.5637665
2025-05-09AKBA2.550.480.1841412
2025-05-12AKBA2.420.480.0641492
2025-05-13AKBA2.480.440.1444526
2025-05-14AKBA2.450.430.0645110
2025-05-15AKBA2.540.430.0145651
2025-05-16AKBA2.620.430.0045013
2025-05-19AKBA2.810.200.4630650
2025-05-20AKBA2.910.230.0032262
2025-05-21AKBA2.80.181.6340438
2025-05-22AKBA2.820.180.1240673
2025-05-23AKBA2.860.190.9041155
2025-05-27AKBA2.910.200.3141453
2025-05-28AKBA2.870.200.0041465
2025-05-29AKBA3.010.190.1541539
2025-05-30AKBA3.040.190.3442318
2025-06-02AKBA3.260.190.0442491
2025-06-03AKBA3.420.180.0144618
2025-06-04AKBA3.640.170.1246800
2025-06-05AKBA3.690.170.0449891
2025-06-06AKBA3.960.170.0050199
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08AKBA2.6252.6- -0.15
2025-05-09AKBA2.55-25.0- -0.15
2025-05-12AKBA2.43-25.0- -0.15
2025-05-13AKBA2.48-25.0- -0.15
2025-05-14AKBA2.45-25.0- -0.15
2025-05-15AKBA2.54-25.0- -0.15
2025-05-16AKBA2.62-25.0- -0.15
2025-05-19AKBA2.800.0- -0.09
2025-05-20AKBA2.910.0- -0.09
2025-05-21AKBA2.810.0- -0.09
2025-05-22AKBA2.820.0- -0.09
2025-05-23AKBA2.860.0- -0.09
2025-05-27AKBA2.920.0- -0.09
2025-05-28AKBA2.870.0- -0.09
2025-05-29AKBA3.010.0- -0.09
2025-05-30AKBA3.030.0- -0.09
2025-06-02AKBA3.260.0- -0.09
2025-06-03AKBA3.420.0- -0.09
2025-06-04AKBA3.640.0- -0.09
2025-06-05AKBA3.690.0- -0.09
2025-06-06AKBA3.9637.5- -0.06
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08AKBA-3.03-1.237.15
2025-05-09AKBA-3.02-1.237.14
2025-05-12AKBA-3.024.647.06
2025-05-13AKBA-3.024.647.06
2025-05-14AKBA-3.014.647.06
2025-05-15AKBA-2.894.647.07
2025-05-16AKBA-2.894.647.07
2025-05-19AKBA-3.019.587.06
2025-05-20AKBA-3.019.587.06
2025-05-21AKBA-3.019.587.06
2025-05-22AKBA-3.019.587.06
2025-05-23AKBA-3.019.587.06
2025-05-27AKBA-3.0149.407.06
2025-05-28AKBA-3.0149.407.83
2025-05-29AKBA-3.0149.407.83
2025-05-30AKBA-3.0149.407.83
2025-06-02AKBA-3.0149.027.83
2025-06-03AKBA-3.0149.027.83
2025-06-04AKBA-3.0149.027.83
2025-06-05AKBA-3.1349.027.83
2025-06-06AKBA-3.1349.027.83
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.03

Avg. EPS Est. Current Quarter

-0.03

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-3.13

Institutional Transactions

49.02

Beta

0.83

Average Sales Estimate Current Quarter

47

Average Sales Estimate Next Quarter

44

Fair Value

Quality Score

40

Growth Score

50

Sentiment Score

91

Actual DrawDown %

71.1

Max Drawdown 5-Year %

-98.2

Target Price

7.4

P/E

Forward P/E

53.65

PEG

P/S

5.64

P/B

42.26

P/Free Cash Flow

EPS

-0.22

Average EPS Est. Cur. Y​

-0.06

EPS Next Y. (Est.)

0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-24.51

Relative Volume

1.56

Return on Equity vs Sector %

-208.4

Return on Equity vs Industry %

-192.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

Akebia Therapeutics, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading